



# **Recent publications in clinical research**

**TRI has published over 75 papers from  
5 key studies...**



# RECENT MANUSCRIPTS

## GARFIELD-AF

1. Camm A.J., Accetta G., Ambrosio G., Atar D., Bassand J.P., Berge E., Cools F., Fitzmaurice D.A., Goldhaber S.Z., Goto S., Haas S., Kayani G., Koretsune Y., Mantovani L.G., Misselwitz F., Oh S., Turpie A.G., Verheugt F.W., Kakkar A.K.; GARFIELD-AF Investigators. **Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.** *Heart* 2017; **103**: 307-14 <http://heart.bmj.com/content/early/2016/09/19/heartjnl-2016-309832.long>
2. Camm A.J., Accetta G., Al Mahmeed W., Ambrosio G., Goldhaber S.Z., Haas S., Jansky P., Kayani G., Misselwitz F., Oh S., Oto A., Raatikainen P., Steffel J., van Eickels M., Kakkar A.K.; GARFIELD-AF Investigators. **Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry.** *BMJ Open* 2017; **7**: e014579 <http://bmjopen.bmj.com/content/7/3/e014579>
3. Fox K.A.A., Gersh B.J., Traore S., Camm A.J., Kayani G., Krogh A., Shweta S., Kakkar A.K., for the GARFIELD-AF Investigators. **Evolving quality standards for large-scale registries: the GARFIELD-AF experience.** *Eur Heart J Qual Care Clin Outcomes* 2017; **3**: 114-22 <https://academic.oup.com/ehjqcco/article-abstract/3/2/114/2687709>
4. Fox K.A.A., Accetta G., Pieper K.S., Bassand J.P., Camm A.J., Fitzmaurice D.A., Kayani G., Kakkar A.K.; GARFIELD-AF Investigators. **Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).** *Eur Heart J Qual Care Clin Outcomes* 2017 Aug 16. doi: 10.1093/ehjqcco/qcx030 <https://academic.oup.com/ehjqcco/article-lookup/doi/10.1093/ehjqcco/qcx030>
5. Corbalán R., Conejeros C., Rey C., Stockins B., Eggers G., Astudillo C., Lanas F., Potthoff S., Houzvic C., Montecinos H., Charme G., Bugeño C., Aguilar J., Arriagada G., Marín P., Larico M., en representación del Grupo GARFIELD AF. **Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile.** *Rev Med Chil* 2017; **145**: 963-71 [Article in Spanish] <http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/5977/3293>
6. Fox K.A.A., Lucas J.E., Pieper K.S., Bassand J.P., Camm A.J., Fitzmaurice D.A., Goldhaber S.Z., Goto S., Haas S., Hacke W., Kayani G., Oto A., Mantovani L.G., Misselwitz F., Piccini J.P., Turpie A.G.G., Verheugt F.W.A., Kakkar A.K.; GARFIELD-AF Investigators. **Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.** *BMJ Open*. 2017 Dec 21;**7(12)**:e017157. doi: 10.1136/bmjopen-2017-017157 <http://bmjopen.bmj.com/cgi/content/full/bmjopen-2017-017157?ijkey=ykllnz2kLYuafXh&keytype=ref>
7. Steinberg B.A., Gao H., Shrader P., Pieper K., Thomas L., Camm A.J., Ezekowitz M.D., Fonarow G.C., Bernard J., Gersh B.J., Goldhaber S., Haas S., Hacke W., Peter R., Kowey P.R., Ansell J., Kenneth W. Mahaffey K.W., Naccarelli G., Reiffel J.A., Turpie A.G.G., FreekVerheugt F.W.A., Piccini J.P., Kakkar A.K., Peterson E.D., Fox K.A.A., For the GARFIELD-AF ORBIT-AF Investigators. **International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.** *Am Heart J* 2017;194:132-40 [http://www.ahjonline.com/article/S0002-8703\(17\)30241-7/pdf](http://www.ahjonline.com/article/S0002-8703(17)30241-7/pdf)
8. Panchenko E.P., Accetta G., Libis P.A., Miller O.H., Novikova T.N., Nagibovich O.A on behalf of the Russian participants in the register GARFIELD-AF. Risk Factors and Prescribed Antithrombotic Therapy in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation in Russian Population: Data From the GARFIELD-AF Registry. *Kardiologija* 2017; **4**: 38-44 DOI: <https://doi.org/10.18565/cardio.2017.4.38-44>.
9. Verheugt F.W.A., Gao H., Mahmeed W.A., Ambrosio G., Angchaisuksiri P., Atar D., Bassand J.P., Camm A.J., Cools F., Eikelboom J., Kayani G., Lim T.W., Misselwitz F., Karen S. Pieper K.S., Eickels M.V., Ajay K. Kakkar A.K., for the GARFIELD-AF Investigators. **Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: Insights from the GARFIELD-AF registry.** *E Heart Journal* 2018; 39(6): 464–473 <https://doi.org/10.1093/eurheartj/ehx730>

10. Bassand J.P., Accetta G., Al Mahmeed W., Corbalan R., Eikelboom J., Fitzmaurice D.A., Fox K.A.A., Gao H., Goldhaber S.Z., Goto S., Haas S., Kayani G., Pieper K., Turpie A.G.G., van Eickels M., Verheugt F.W.A., Kakkor A.K., GARFIELD-AF Investigators. **Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.** *PLoS One* 2018; 25:13(1):e0191592. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784935/pdf/pone.0191592.pdf>
11. Apenteng P.N., Gao H., Hobbs F.D.R., David A Fitzmaurice D.A, On behalf of UK GARFIELD-AF Investigators and GARFIELD-AF Steering Committee. **Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.** *BMJ Open* 2018; 8:e018905. <http://bmjopen.bmj.com/content/bmjopen/8/1/e018905.full.pdf>
12. Le Heuzeya J-Y., Bassand J-P., Berneau J-P., Cozzolino P., D'Angiolella L., Doucet B., Mantovani L.G., Martelet M., Mouallem J., Muller J.J., Pieper K.S., for the GARFIELD-AF Investigators. **Stroke prevention, 1-year clinical outcomes, and healthcare resource utilisation in patients with atrial fibrillation in France: data from the GARFIELD-AF registry.** *Arch Cardiovasc Dis* (2018). <https://doi.org/10.1016/j.acvd.2018.03.012>
13. Cools F, Wollaert B., Vervoort G, Verstraete S., Voet J, Hermans J., Heyse A., De Wolf A., Hollanders G., Boussy T., Anné W., Vercammen J., Faes D., Beutels M., Mairesse G., Purnode P., Blankoff I., Vandergoten P., Capiou L., Allu J., Bassand J-P., Kayani G., for the GARFIELD-AF Investigators. **Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry.** *Acta Cardiol.* 2018 Oct 27:1-10. <https://www.ncbi.nlm.nih.gov/pubmed/30369290>
14. Sawhney J.P.S., Kothiwale V.A., Bisne V., Durgaprasad R., Jadhav P., Chopda M., Vanajakshamma V., Meena R., Vijayaraghavan G, Chawala K., Jagan A., Pieper K.S., Camm A.J., Kakkor A.K., for the GARFIELD-AF investigators. **Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights into the GARFIELD-AF Registry.** *Indian Heart Journal* xxx (2018) 1e8. <https://www.sciencedirect.com/science/article/pii/S0019483218303699>
15. Koretsune Y., Etoh T., Katsuda Y., Suetsugu T., Kumeda K., Sakuma I., Eshima K., Shibuya M., Ando S., Yokota N., Goto S., Piper K.S., Jagan A., Kakkor A.K., for the GARFIELD-AF investigators. **Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in Japan: Insights from the GARFIELD-AF Registry.** (Ahead of Print in *Circ J*, 2018).
16. Bassand J-P., Virdone S., Goldhaber S.Z., Camm A.J., Fitzmaurice D.A., Fox K.A.A., Goto S., Haas S., Hacke W., Kayani G., Mantovani L.G., Misselwitz F., Pieper K.S., Turpie A.G.G., van Eickels M., Verheugt F.W.A., Kakkor A.K., for the GARFIELD-AF investigators. **Early risks of death, stroke/systemic embolism and major bleeding in patients with newly diagnosed atrial fibrillation: Results from the GARFIELD-AF registry.** (Ahead of Print in *Circulation*, 2018). <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.035012>
17. Goto S., Angchaisuksiri P., Bassand J-P., Camm A.J., Dominguez H., Illingworth L., Gibbs H., Goldhaber S.Z., Goto S., Jing J-Z., Haas S., Kayani G., Koretsune Y., Lim T.W., Oh S., Sawhney J.P.S., Turpie A.G.G., van Eickels M., Verheugt F.W.A., Kakkor A.K., for the GARFIELD-F Investigators. **Management and 1-Year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: results from the prospective GARFIELD-AF registry.** *J AM Heart Assoc.* 2019 8:e105 10. <https://www.ahajournals.org/doi/10.1161/JAHA.118.010510>.
18. Jerjes-Sanchez C., Corbalan R., Barretto ACP., Luciardi HL., Jagan A., Illingworth L., Pieper KS., Kayani G., for the GARFIELD-AF Investigators. **Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry.** *Clinical Cardiology.* 2019; 42:553–560. <https://onlinelibrary.wiley.com/doi/full/10.1002/clc.23176>
19. Corbalan R., Bassand J-P., Illingworth L., Ambrosio G., Camm AJ., Fitzmaurice DA., Fox KAA., Goldhaber SZ., Goto S., Haas S., Kayani G., Mantovani LG., Misselwitz F., Pieper KS., Turpie AGG., Verheugt FWA., Kakkor AK., for the GARFIELD-AF Investigators. **Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients with Atrial Fibrillation a Report from the GARFIELD-AF Registry.** *JAMA Cardiol.* 2019; 4(6):526-548. <https://jamanetwork.com/journals/jamacardiology/fullarticle/2732488>
20. Haas S., Camm AJ., Bassand J-P., Angchaisuksiri P., Cools F., Corbalan R., Gibbs H., Jacobson B., Koretsune Y., Mantovani LG., Misselwitz F., Panchenko E., Ragy HI., Stepinska J., Turpie AGG., Sawhney JPS., Steffel J., Lim TW., Pieper KS., Virdone S., Verheugt FWA., Kakkor AK., for the GARFIELD-AF Investigators. **Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.** *AHJ.* 2019; 213; 35-46. <https://www.sciencedirect.com/science/article/pii/S0002870319300791?via%3Dihub>
21. Atar D., Berge E., Le Heuzey., Virdone S., Camm AJ., Steffel J., Gibbs H., Goldhaber SZ., Goto S., Kayani G., Misselwitz F., Stepinska J., Turpie AGG., Bassand J-P., Kakkor AK., for the investigators. **The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events.** *Europace.* 2019; 0: 1–10. <http://openaccess.sgul.ac.uk/11442/1/euz292.pdf>

22. Verheugt FWA., Ambrosio G., Atar D., Bassand J-P., Camm AJ., Costabel JP., Fitzmaurice DA., Illingworth L., Goldhaber SZ., Goto S., Haas S., Jansky P., Kayani G., Stepinska J., Turpie AGG., van Eickels M., Kakkar AK., for the GARFIELD-AF Investigators. **Outcomes in newly diagnosed atrial fibrillation and history of acute coronary syndromes: insights from GARFIELD-AF.** [https://www.amjmed.com/article/S0002-9343\(19\)30543-1/fulltext](https://www.amjmed.com/article/S0002-9343(19)30543-1/fulltext)
23. Hacke W., Bassand J-P., Virdone S., Camm AJ., Fitzmaurice DA., Fox KAA., Goldhaber SZ., Goto S., Haas S., Kayani G., Mantovani LG., Misselwitz F., Pieper KS., Turpie AGG., van Eickels M., Verheugt FWA., Kakkar AK., for the GARFIELD-AF Investigators. **Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry.** International Journal of Stroke 0(0) 1–10. <https://journals.sagepub.com/doi/10.1177/1747493019891516>
24. Verbrugge FH., Martin A-C., Siegal D., Fiarresga A., Pieper KS., Illingworth L., Camm AJ., Fox KAA., Bassand J-P., Haas S., Goldhaber SZ., Kakkar AK. **Impact of Oral Anticoagulation in Atrial Fibrillation Patients at Very Low Thromboembolic Risk.** Heart. 2019. <http://dx.doi.org/10.1136/heartjnl-2019-315873>
25. Goto S, Goto S, Pieper KS, Bassand J-P, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Haas S, Parkhomenko A, Oto A, Misselwitz F, Turpie AGG, Verheugt FWA, Fox KAA, Gersh BJ, Kakkar AK for the GARFIELD-AF Investigators. **New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF.** EHJ – CVP. DOI.201910.1093/ehjcvp/pvz076. <https://academic.oup.com/ehjcvp/advance-article/doi/10.1093/ehjcvp/pvz076/5671699>
26. Fox KAA, Velentgas P, Camm AJ, Bassand J-P, Fitzmaurice DA, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Dabrowski E, Luo K, Gibbs L, Kakkar AK, for the GARFIELD-AF Investigators. **Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation.** JAMA Network Open. 2020;3(2):e200107. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2761869>
27. Dalgaard F, Pieper K, Verheugt FWA, Camm AJ, Fox KAA, Kakkar AK, Pallisgaard JL, Rasmussen PV, van Weert H, Lindhardt TB, Torp-Pedersen C, Gislason GH, Ruwald MH, Harskamp. **GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study.** BMJ Open 2019;9:e033283 <https://bmjopen.bmj.com/content/9/11/e033283>
28. Seelig J, Verheugt FWA, M. E. W. Hemels MEW, Illingworth L, Lucassen A, Adriaansen H, Bongaerts MCM, M. Pieterse M, Herrman JPR, Hoogslag P, Hermans W, Groenemeijer BE, Boersma LVA, Pieper K, ten Cate H and on behalf of the GARFIELD-AF Investigators. **Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registry.** Thrombosis Journal. 2020: 18:5. <https://thrombosisjournal.biomedcentral.com/articles/10.1186/s12959-020-00218-x>
29. Bassand J-P, Apenteng PN, Atar D, Camm AJ, Cools F, Corbalan R, Fitzmaurice DA, Fox KAA, Goto S, Haas S, Hacke W, Jerjes-Sanchez C, Koretsune Y, Le Heuzey J-Y, Sawhney JPS, Oh S, Stepinska J, ten Cate V, Verheugt FWA, Kayani G, Pieper KS, Kakkar AK for the GARFIELD-AF Investigators. **GARFIELD-AF (Global Anticoagulant Registry in the FIELD – Atrial Fibrillation), a worldwide prospective registry of patients with atrial fibrillation at risk of stroke.** Future Cardiology 2020 Jul 22. doi: 10.2217/fca-2020-0014. <https://www.futuremedicine.com/doi/pdf/10.2217/fca-2020-0014>
30. Loring Z, Mehrotra S, Piccini JP, Camm AJ, Carlson D, Fonarow GC, Fox KAA, Peterson ED, Pieper K, Kakkar AK. **Machine Learning Does Not Improve Upon Traditional Regression in Predicting Outcomes in Atrial Fibrillation: An Analysis of the ORBIT-AF and GARFIELD-AF Registries.** EP Europace, euaa172. <https://doi.org/10.1093/europace/euaa172>
31. Camm AJ, Cools F, Virdone S, Bassand J-P, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Mantovani LG, Kayani G, Turpie AGG, Verheugt FWA, Kakkar AJ for the GARFIELD-AF Investigators. **Mortality in Patients with Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants.** J Am Coll Cardiol. 2020; 76(12):1425–36. <https://www.sciencedirect.com/science/article/pii/S0735109720361052?via%3Dihub>
32. Jaap S, Hemels MEW, Xhaet O, Bongaerts MCM, de Wolf A, Groenemeijer BE, Heyse A, Hoogslag P, Voet J, Herrman J-P R, Vervoort G, Hermans W, Wollaert B, Boersma LVA, Hermans K, Lucassen A, Verstraete S, Adriaansen HJ, Mairesse GH, Terpstra WF, Faes D, Pieterse M, Virdone S, Verheugt FWA, Cools F, Ten Cate H for the GARFIELD-AF investigators. **Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD-AF registry.** J Thromb Haemost. 2020 Sep 4. doi: 10.1111/jth.15081. <https://onlinelibrary.wiley.com/doi/full/10.1111/jth.15081>
33. Camm AJ, Fox KAA, Virdone S, Bassand J-P, Fitzmaurice DA, Berchuck SI, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Cappato R, Kakkar AJ, for the GARFIELD-AF investigators. **Comparative effectiveness of oral anticoagulants in everyday practice.** Camm AJ, et al. Heart 2021; 0:1–9. doi:10.1136/heartjnl-2020-318420. <https://heart.bmj.com/content/early/2021/02/15/heartjnl-2020-318420>

34. Bassand J-P, Virdone S, Badoz M, Verheugt FWA, Camm AJ, Cools F, Fox KAA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Kakkar AJ, for the GARFIELD-AF Investigators. **Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry.** *Bloodadvances*. 2021;5(4): 1081-1091. <https://www.sciencedirect.com/science/article/pii/S2473952921001300>
35. Ambrosio G, Camm AJ, Bassand JP, Corbalan R, Kayani G, Carluccio E, Mantovani LG, Virdone S, Kakkar AK; GARFIELD-AF Investigators. **Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD-AF.** *ESC Heart Fail*. 2021 Jan 12. doi: 10.1002/ehf2.13156. Epub ahead of print. PMID: 33434417. <https://pubmed.ncbi.nlm.nih.gov/33434417/>
36. Gibbs H, Freedman B, Rosenqvist M, Virdone S, Al Mahmeed W, Ambrosio G, Camm AJ, Connolly SJ, Jacobson B, Jerjes-Sanchez C, Kayani G, Oto A, Panchenko E, Ragy H, Kakkar AJ, for the GARFIELD-AF Investigators. **Clinical outcomes in asymptomatic and symptomatic patients with newly diagnosed atrial fibrillation in GARFIELD-AF: Implications for screening for atrial fibrillation.** *American J of Medicine The American Journal of Medicine*, Vol 000, No 000, 2021 [https://www.amjmed.com/article/S0002-9343\(21\)00096-6/pdf](https://www.amjmed.com/article/S0002-9343(21)00096-6/pdf).
37. Pope MK, Atar D, Svilaas A, HoleT, Nielsen JD, Hintze U, Crisby M, Raatikainen P, Airaksinen KEJ, Virdone S, Pieper K, Kayani G, Le Heuzey J-Y, Steffel J, Stepinska J, Bassand J-P, Camm AJ for the GARFIELD-AF Investigators. **Risk profile, Antithrombotic Treatment and Clinical Outcomes of patients in Nordic Countries with Atrial Fibrillation- Results from the GARFIELD-AF Registry.** *Annals of Medicine* *Annals of Medicine*, 53:1, 485-494, DOI:10.1080/07853890.2021.1893897.
38. Fox KAA, Virdone S, Pieper KS, Bassand J-P, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Oto A, Misselwitz F, Piccini JP, Dalgaard F, Turpie AGG<sup>13</sup>, Verheugt FWA and Kakkar AK for the GARFIELD-AF Investigators. **GARFIELD-AF risk score for mortality, stroke and bleeding within 2 years in patients with atrial fibrillation.** *Eur Heart J Qual Care Clin Outcomes*. 2021 Apr 21:qcab028. doi: 10.1093/ehjqcco/qcab028.
39. Sayin BY, Mahameed WAL, Ragy HI, Elabhary A, Virdone S, Kakkar AJ, Ersanli M, Oto A. **Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from GARFIELD-AF Study.** *Advances in Therapy* volume 38, pages2391–2405 (2021).
40. Cools F, Johnson D, Camm AJ, Bassand J-P, Verheugt FWA, Yang S, Tsiatis A, Fitzmaurice DA, Goldhaber SZ, Kayani G, Goto S, Haas S, Misselwitz F, Turpie AGG, Fox KAA, Pieper KS, Kakkar AK for the GARFIELD-AF Investigators. **Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry.** *J Thromb Haemost*. 2021 Jun 1. doi: 10.1111/jth.15415.
41. Pope MK, Hall TS, Schirripa V, Radic P, Virdone S, Pieper KS, Le Heuzey JY, Jansky P, Fitzmaurice DA, Cappato R, Atar D, Camm AJ, Kakkar AK; GARFIELD-AF investigators. **Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data.** *BMJ*. 2021 Oct 27;375:e066450. doi: 10.1136/bmj-2021-066450. PMID: 34706884; PMCID: PMC8548918.
42. Farjat AE, Virdone S, Thomas LE, Kakkar AK, Pieper KS, Piccini JP. **The importance of the design of observational studies in comparative effectiveness research: Lessons from the GARFIELD-AF and ORBIT-AF registries.** *Am Heart J*. 2022 Jan;243:110-121. doi: 10.1016/j.ahj.2021.09.003. Epub 2021 Sep 13. PMID: 34529945.
43. Fox KAA, Virdone S, Bassand JP, Camm AJ, Goto S, Goldhaber SZ, Haas S, Kayani G, Koretsune Y, Misselwitz F, Oh S, Piccini JP, Parkhomenko A, Sawhney JPS, Stepinska J, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF investigators\*. **Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry.** *BMJ Open*. 2022 Jan 7;12(1):e049933. doi: 10.1136/bmjopen-2021-049933. PMID: 34996784; PMCID: PMC8744109.
44. Johnson, D, Pieper, K, Yang, S. **Treatment-specific marginal structural Cox model for the effect of treatment discontinuation.** *Pharmaceutical Statistics*. 2022; 1- 17. doi:[10.1002/pst.2211](https://doi.org/10.1002/pst.2211)
45. **Two-year outcomes of UK patients newly diagnosed with atrial fibrillation: findings from the prospective observational cohort study GARFIELD-AF.** Patricia N Apenteng, Saverio Virdone, FD Richard Hobbs, A John Camm, Keith AA Fox, Karen S Pieper, Gloria Kayani and David Fitzmaurice for the GARFIELD UK investigators\* *British Journal of General Practice* 16 May 2022; BJGP.2021.0548. DOI: <https://doi.org/10.3399/BJGP.2021.0548>; PMID: 35577587
46. **Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis.** Georg van Husen, Saverio Virdone, Karen Pieper, Gloria Kayani, Keith A.A. Fox. *European Heart Journal - Digital Health*, ztac011, DOI: <https://doi.org/10.1093/ehjdh/ztac011>

# GARFIELD-VTE

1. Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Pieper KS, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK. **Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry.** *Thromb Haemost.* 2019 Feb;119(2):319-327. <https://doi.org/10.1055/s-0038-1676611>
2. Haas S, Ageno W, Weitz JI, Turpie AGG, Goto S, Angchaisuksiri P, Dalsgaard Nielsen J, Kayani G, Zaghdoun A, Farjat AE, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK. **Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.** *J Thromb Haemost.* 2019 Oct;17(10):1694-1706. <https://doi.org/10.1111/jth.14548>
3. Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Pieper KS, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK. **Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry.** *Thromb Haemost.* 2019 Aug;119(8):1365-1372. <https://doi.org/10.1055/s-0039-1688828>
4. Schellong S, Goldhaber SZ, Weitz JI, Ageno W, Bounameaux H, Turpie AGG, Angchaisuksiri P, Haas S, Goto S, Zaghdoun A, Farjat A, Nielsen JD, Kayani G, Mantovani LG, Prandoni P, Kakkar AK. **Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry.** *Thromb Haemost.* 2019 Oct;19(10):1675-1685. <https://doi.org/10.1055/s-0039-1693461>
5. Bounameaux H, Haas S, Farjat AE, Ageno W, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Schellong S, Mantovani LG, Prandoni P, Kakkar AK. **Comparative Effectiveness of Oral Anticoagulants in Venous Thromboembolism: GARFIELD-VTE.** *Thromb Res.* 2020 Jul;191:103-112. Epub 2020 Apr <https://doi.org/10.1016/j.thromres.2020.04.036>
6. Weitz JI, Haas S, Ageno W, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Farjat AE, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK. **Cancer Associated Thrombosis in Everyday Practice: Perspectives from GARFIELD-VTE.** *J Thromb Thrombolys.* In press – June 2020.
7. Goto S, Haas S, Ageno W, Goldhaber SZ, Turpie AGG, Weitz JI, Angchaisuksiri P, Nielsen JD, Kayani G, Farjat A, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE Investigators. **Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease.** *JAMA Netw Open.* 2020 Oct 1;3(10):e2022886. <https://doi.org/10.1001/jamanetworkopen.2020.22886>
8. Jerjes-Sánchez C, Rodríguez D, Farjat AE, Kayani G, MacCallum P, Lopes RD, Turpie AGG, Weitz JI, Haas S, Ageno W, Goto S, Goldhaber SZ, Angchaisuksiri P, Nielsen JD, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE investigators. **Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE.** *TH Open.* 2021 Jan 27;5(1):e24-e34. <https://doi.org/10.1055/s-0040-1722611>
9. Ageno W, Farjat A, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Dalsgaard Nielsen J, Kayani G, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK. **Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE.** *Res Pract Thromb Haemost.* 2021 Feb 20;5(2):326-341. <https://doi.org/10.1002/rth2.12482>
10. Angchaisuksiri P, Goto S, Farjat AE, Fryk H, Bang SM, Chiang CE, Jing ZC, Kondo K, Sathar J, Tse E, Phusanti S, Kayani G, Weitz JI, Ageno W, Goldhaber SZ, Kakkar AK. **Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE.** *Thromb Res.* 2021 May;201:63-72. <https://doi.org/10.1016/j.thromres.2021.02.024>
11. Goto S, Turpie AGG, Farjat AE, Weitz JI, Haas S, Ageno W, Goldhaber SZ, Angchaisuksiri P, Kayani G, MacCallum P, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE investigators. **The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD- VTE.** <https://doi.org/10.1016/j.thromres.2021.05.007>

12. Weitz JI, Farjat AE, Ageno W, Turpie AGG, Haas S, Goto S, Goldhaber SZ, Angchaisuksiri P, Gibbs H, MacCallum P, Carrier M, Kayani G, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE Investigators. **Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE.** J Thromb Haemost. 2021 Dec;19(12):3031-3043. <https://doi.org/10.1111/jth.15520>
13. Cohen O, Ageno W, Farjat AE, Turpie AGG, Weitz JI, Haas S, Goto S, Goldhaber SZ, Angchaisuksiri P, Gibbs H, MacCallum P, Kayani G, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE investigators. **Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE.** J Thromb Haemost. 2022 Feb;20(2):366-374. <https://doi.org/10.1111/jth.15574>

## RIVER

1. Beyer-Westendorf J., Camm AJ., Fox KAA., Le Heuzey J-Y., Haas S., Turpie AGG., Virdone S., Kakkar AK., for the RIVER Registry Investigators. **International Longitudinal Registry of Patients with Atrial Fibrillation and Treated with Rivaroxaban: RIVaroxaban Evaluation in Real Life setting (RIVER).** Thromb J. 2019 Apr 25;17:7. <https://doi.org/10.1186/s12959-019-0195-7>

## FRONTLINE

1. Kakkar AK, Bauersachs R, Falanga A, Wong J, Kayani G, Kahney A, Hughes R, Levine M. **Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey.** The Oncologist. 2020; 25:1-7. <https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2019-0676>

## ETHIC

1. Cools F, Virdone S, Sawhney J, Lopes RD, Jacobson B, Arcelus JI, Hobbs FDR, Gibbs H, Himmelreich JCL, MacCallum P, Schellong S, Haas S, Turpie AGG, Ageno W, Rocha AT, Kayani G, Pieper K, Kakkar AK; ETHIC investigators. **Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial.** Lancet Haematol. 2022 Aug;9(8):e594-e604. doi:10.1016/S2352-3026(22)00173-9.